chemotherapy for 4–8 months than women with stage IA tumors
(OR = 2.22; 95% CI, 1.37–3.59). In contrast, those who underwent
lymphadenectomy (OR=0.51; 95% CI, 0.34–0.79)were less likely to receive
longer duration chemotherapy. Among high-risk women who received
chemotherapy and after adjustment for clinical and oncologic
characteristics, the duration of chemotherapy had no effect on either
cancer-specific (HR = 0.93; 95% CI, 0.61–1.42) or overall (HR = 0.93;
95% CI, 0.67–1.27) survival. Likewise, in a Kaplan–Meier analysis, the
duration of chemotherapy had no effect on survival (P= 0.76).